Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study

Sorafenib is an oral multikinase inhibitor that has been approved to treat advanced hepatocellular carcinoma (HCC), though it is unclear how much benefit advanced HCC patients with progressive disease (PD) derive from sorafenib treatment. This study aimed to assess survival risk factors and evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, Masahito, Tanaka, Masatoshi, Kuromatsu, Ryoko, Nagamatsu, Hiroaki, Satani, Manabu, Niizeki, Takashi, Okamura, Shusuke, Iwamoto, Hideki, Shimose, Shigeo, Shirono, Tomotake, Noda, Yu, Koga, Hironori, Torimura, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325452/
https://www.ncbi.nlm.nih.gov/pubmed/27462865
http://dx.doi.org/10.18632/oncotarget.10794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325452/
https://www.ncbi.nlm.nih.gov/pubmed/27462865
http://dx.doi.org/10.18632/oncotarget.10794

Ejemplares similares